Alembic Pharma

APLLTD26 Apr 2024

Pharmaceuticals

₹

-7.25 (-0.73%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Alembic Pharma

Alembic Pharma

Pharmaceuticals

APLLTD26 Apr 2024

₹

-7.25 (-0.73%)

OverviewFundamentals

Corporate action

Peer comparison

Income Sheet

Balance sheet

Cash flow

Share holding

About Us

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date
05-May-2023	D	The exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has inter alia Approved the Audited Financial Results for the quarter and financial year ended 31st March, 2023. and Recommended a dividend of Rs. 8/- (400%) per Equity Share. The Company has fixed Friday, 28th July, 2023 as the record date for determining the entitlement of Members to final dividend for the financial year ended 31st March, 2023. (As Per BSE Announcement Dated on 21.06.2023)	28-Jul-2023
02-May-2022	D	Alembic Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 02, 2022, inter alia, has recommended a dividend of Rs. 10/- (500%) per Equity Share having face value of Rs. 2/- each, subject to approval of the Shareholders at the ensuing Annual General Meeting. With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has inter alia approved: 1) Unaudited Financial Results for the quarter ended 30th June, 2022. 2) Re-classification of the dividend of Rs. 10/- (500%) per equity share for the financial year 2021-22, recommended by them at their meeting held on 2nd May, 2022, into interim dividend for the financial year 2021-22. Please note that the said interim dividend will be paid to those shareholders whose names appear on the Register of Members as on the Record Date fixed for the purpose i.e. Thursday, 18th August, 2022. No further final dividend for the financial year 2021-22 shall be declared. The time of commencement of the Board Meeting was 12:30 p.m. and the time of conclusion was 3:30 p.m. We request you to kindly take the same on record. (As Per BSE Announcement Dated on 04.08.2022)	17-Aug-2022
04-May-2021	D	Outcome Of Board Meeting Please find attached herewith covering letter along with the documents Recommended a dividend of Rs.14/- (700%) per Equity Share having face value of Rs. 2/- each, subject to approval of the Shareholders at the ensuing Annual General Meeting	19-Jul-2021
06-Mar-2020	D	With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has declared Interim Dividend of Rs. 7.00/- (350%) per equity share of Rs. 2/- each for the financial year 2019-20 vis-a-vis Rs. 5.50/- (275%) per equity share for the previous year. Further, the Board of Directors declared additional Special Dividend of Rs. 3.00/- (150%) per equity share for the financial year 2019-20. The total Interim Dividend of Rs. 10.00/- (500%) per equity share will be paid to those shareholders whose names appear on the Register of Members as on the Record Date fixed for the purpose i.e. Tuesday, 17th March, 2020. The time of commencement of the Board Meeting was 11:30 a.m. and the time of conclusion was 12:20 p.m. We request you to kindly take the same on record.	16-Mar-2020
06-Mar-2020	D	With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has declared Interim Dividend of Rs. 7.00/- (350%) per equity share of Rs. 2/- each for the financial year 2019-20 vis-a-vis Rs. 5.50/- (275%) per equity share for the previous year. Further, the Board of Directors declared additional Special Dividend of Rs. 3.00/- (150%) per equity share for the financial year 2019-20. The total Interim Dividend of Rs. 10.00/- (500%) per equity share will be paid to those shareholders whose names appear on the Register of Members as on the Record Date fixed for the purpose i.e. Tuesday, 17th March, 2020. The time of commencement of the Board Meeting was 11:30 a.m. and the time of conclusion was 12:20 p.m. We request you to kindly take the same on record.	16-Mar-2020
08-May-2019	D	Alembic Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 08, 2019, inter alia, has recommended a dividend of Rs. 5.50/- (275%) per Equity Share having face value of Rs. 2/- each, subject to approval of the Shareholders at the ensuing Annual General Meeting.	18-Jul-2019
16-May-2018	D	Recommended a dividend of Rs. 4.00 (200%) per Equity Share having face value of Rs. 2/- each, subject to approval of the Shareholders at the ensuing Annual General Meeting.	18-Jul-2018
03-May-2017	D	With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has inter alia: 1. Approved the Audited Financial Results of the Company for the financial year ended 31st March, 2017. 2. Recommended a dividend of Rs. 4.00 (200%) per Equity Share of face value of Rs. 2 each, subject to approval of the Shareholders at the ensuing Annual General Meeting. We enclose herewith the following:	11-Jul-2017
27-Apr-2016	D	Alembic Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on April 27, 2016, inter alia, has : 1. Recommended a dividend of Rs. 4.00 (200%) per Equity Share of face value of Rs. 2 each, subject to approval of Shareholders at the ensuing Annual General Meeting.	20-Jul-2016
27-Apr-2015	D	Alembic Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on April 27, 2015, inter alia, has recommended a dividend of Rs. 3.50 (175%) per Equity Share of face value of Rs. 2 each, subject to approval of Shareholders at the ensuing Annual General Meeting.	22-Jul-2015
28-Apr-2014	D	Alembic Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on April 28, 2014, inter alia, has recommended a dividend of Rs. 3.00 (150%) per Equity Share of Rs. 2 each, subject to approval of Shareholders at the Annual General Meeting.	17-Jul-2014
02-May-2013	D	Alembic Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 02, 2013, inter alia, have taken the following decisions : 1. The Board has recommended a dividend of Rs. 2.50 (125%) per Equity Share of Re. 2 each, subject to approval of Shareholders at the Annual General Meeting.	29-Jul-2013
25-Apr-2012	D	Alembic Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on April 25, 2012, inter alia, has recommended dividend Rs. 1.40 per Equity Share i.e. @ 70% on 18,85,15,914 Equity Shares of Rs. 2/- each for the year ended on March 31, 2012.	31-Jul-2012
29-Mar-2024	BC	The Board of Directors at its Meeting held today has approved the appointment of Mr. Manish Kejriwal (DIN: 00040055) as an Independent Director of the Company for a period of 5 consecutive years w.e.	12-May-2024
18-Apr-2024	BC	ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/05/2024 inter alia to consider and approve 1. Audited Financial Results of th	09-May-2024
29-Mar-2024	BC	The Board of Directors at its Meeting held today has approved the appointment of Mr. Manish Kejriwal (DIN: 00040055) as an Independent Director of the Company for a period of 5 consecutive years w.e.	31-Mar-2024
01-Apr-2024	BC	Please find attached herewith the intimation for completion of tenure of the Independent Directors of the Company w.e.f. end of the day on 31st March. 2024.	31-Mar-2024
29-Mar-2024	BC	The Board of Directors at its Meeting held today has approved the appointment of Mr. Manish Kejriwal (DIN: 00040055) as an Independent Director of the Company for a period of 5 consecutive years w.e.	29-Mar-2024

Announcement Date05-May-2023

Ex Dividend Date28-Jul-2023

Dividend(%)400

Announcement Date02-May-2022

Ex Dividend Date17-Aug-2022

Dividend(%)500

Announcement Date04-May-2021

Ex Dividend Date19-Jul-2021

Dividend(%)700

Announcement Date06-Mar-2020

Ex Dividend Date16-Mar-2020

Dividend(%)150

Announcement Date06-Mar-2020

Ex Dividend Date16-Mar-2020

Dividend(%)350

Announcement Date08-May-2019

Ex Dividend Date18-Jul-2019

Dividend(%)275

Announcement Date16-May-2018

Ex Dividend Date18-Jul-2018

Dividend(%)200

Announcement Date03-May-2017

Ex Dividend Date11-Jul-2017

Dividend(%)200

Announcement Date27-Apr-2016

Ex Dividend Date20-Jul-2016

Dividend(%)200

Announcement Date27-Apr-2015

Ex Dividend Date22-Jul-2015

Dividend(%)175

Announcement Date28-Apr-2014

Ex Dividend Date17-Jul-2014

Dividend(%)150

Announcement Date02-May-2013

Ex Dividend Date29-Jul-2013

Dividend(%)125

Announcement Date25-Apr-2012

Ex Dividend Date31-Jul-2012

Dividend(%)70

No Rights has been declared by APLLTD

Book Closure

Record Date	Split Date	Purpose
12-May-2024	01 Jan'1900	The Board of Directors at its Meeting held today has approved the appointment of Mr. Manish Kejriwal (DIN: 00040055) as an Independent Director of the Company for a period of 5 consecutive years w.e.
09-May-2024	-	ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/05/2024 inter alia to consider and approve 1. Audited Financial Results of th
31-Mar-2024	-	The Board of Directors at its Meeting held today has approved the appointment of Mr. Manish Kejriwal (DIN: 00040055) as an Independent Director of the Company for a period of 5 consecutive years w.e.
31-Mar-2024	-	Please find attached herewith the intimation for completion of tenure of the Independent Directors of the Company w.e.f. end of the day on 31st March. 2024.
29-Mar-2024	-	The Board of Directors at its Meeting held today has approved the appointment of Mr. Manish Kejriwal (DIN: 00040055) as an Independent Director of the Company for a period of 5 consecutive years w.e.

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Alembic Pharmaceuticals Ltd ₹990.25(-7.25/-0.73%)	990.25	-7.25	19,464.66	80.50	32.72	4.34
Lupin Ltd ₹1,615.95(+21.55/1.35%)	1,615.95	+21.55	73,646.94	128.34	35.73	3.82
Ipca Laboratories Ltd ₹1,338.50(+10.05/0.76%)	1,338.50	+10.05	33,958.31	90.83	61.69	5.47
J B Chemicals & Pharmaceuticals Ltd ₹1,865.05(+2.25/0.12%)	1,865.05	+2.25	28,944.61	77.48	57.14	10.78
Sanofi India Ltd ₹8,274.15(+120.75/1.48%)	8,274.15	+120.75	19,055.37	38.57	32.28	18.77
IOL Chemicals & Pharmaceuticals Ltd ₹399.50(-0.85/-0.21%)	399.50	-0.85	2,345.28	-2.77	13.60	1.48

Income Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	1588.39	1478.84	1332.27	1307.12	1310.21	1354.42
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	1588.39	1478.84	1332.27	1307.12	1310.21	1354.42
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	3.30	8.95	11.84	1.96	0.58	0.47
Total Income	1591.69	1487.79	1344.11	1309.08	1310.79	1354.89
Total Expenditure	1251.25	1271.38	1166.54	1137.94	1085.98	1109.13
PBIDT	340.44	216.41	177.57	171.14	224.81	245.76
Interest	14.66	15.39	14.29	13.59	14.65	11.96
PBDT	325.78	201.02	163.28	157.55	210.16	233.80
Depreciation	69.08	67.18	65.75	73.54	65.85	66.80
Tax	23.46	0.00	0.00	-46.53	25.18	20.56
Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
Reported Profit After Tax	233.24	133.84	97.53	130.54	119.13	146.44
Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	233.24	133.84	97.53	130.54	119.13	146.44

EPS (Unit Curr.)	11.87	6.81	4.96	6.64	6.06	7.45
EPS (Adj) (Unit Curr.)	11.87	6.81	4.96	6.64	6.06	7.45
Calculated EPS (Unit Curr.)	11.87	6.81	4.96	6.64	6.06	7.45
Calculated EPS (Adj) (Unit Curr.)	11.87	6.81	4.96	6.64	6.06	7.45
Calculated EPS (Ann.) (Unit Curr.)	47.47	27.24	19.85	26.57	24.24	29.80
Calculated EPS (Adj) (Ann.) (Unit Curr.)	47.47	27.24	19.85	26.57	24.24	29.80
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	39.31	39.31	39.31	39.31	39.31	39.31
Reserve & Surplus	0.00	0.00	0.00	0.00	0.00	0.00
Face Value	2.00	2.00	2.00	2.00	2.00	2.00

Public Shareholding (No. Of Shares)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (% in Equity)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	21.43	14.63	13.33	13.09	17.16	18.15
PBDTM(%)	20.51	13.59	12.26	12.05	16.04	17.26
PATM(%)	14.68	9.05	7.32	9.99	9.09	10.81

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	1630.57	1594.93	1486.15	1406.45	1509.02	1475.01
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	1630.57	1594.93	1486.15	1406.45	1509.02	1475.01
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	2.89	10.15	11.67	0.89	0.44	0.33
Total Income	1633.46	1605.08	1497.82	1407.34	1509.46	1475.34
Total Expenditure	1364.25	1387.19	1287.49	1202.68	1273.86	1243.92
PBIDT	269.21	217.89	210.33	204.66	235.60	231.42
Interest	15.17	15.69	14.39	14.37	14.60	12.41
PBDT	254.04	202.20	195.94	190.29	221.00	219.01
Depreciation	69.45	67.56	66.18	74.12	66.51	67.70
Minority Interest Before NP	0.00	0.00	0.00	0.00	0.00	0.00
Tax	27.84	3.54	4.29	-50.19	28.46	23.86
Deferred Tax	-23.70	-5.46	4.87	13.76	4.11	-5.90
Reported Profit After Tax	180.45	136.56	120.60	152.60	121.92	133.35
Minority Interest After NP	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit after Minority Interest	180.45	136.56	120.60	152.60	121.92	133.35

Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	180.45	136.56	120.60	152.60	121.92	133.35

EPS (Unit Curr.)	9.23	6.95	6.14	7.76	6.20	6.78
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	39.31	39.31	39.31	39.31	39.31	39.31

Public Shareholding (Number)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (%)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	16.51	13.66	14.15	14.55	15.61	15.69
PBDTM(%)	15.58	12.68	13.18	13.53	14.65	14.85
PATM(%)	11.07	8.56	8.11	10.85	8.08	9.04

Balance Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	39.31	39.31	39.31	37.70	37.70	37.70
Reserves Total	4374.98	5251.03	5062.50	3308.31	2674.71	2156.94
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	4414.29	5290.34	5101.81	3346.01	2712.41	2194.64
Secured Loans	165.07	0.00	0.02	0.04	34.93	46.53
Unsecured Loans	544.86	706.12	583.59	1686.99	1024.35	575.00
Total Debt	709.93	706.12	583.61	1687.03	1059.28	621.53
Total Liabilities	5124.22	5996.46	5685.42	5033.04	3771.69	2816.17
APPLICATION OF FUNDS :
Gross Block	3605.68	2733.10	2452.31	1761.67	1435.06	1162.61
Less : Accumulated Depreciation	1228.23	962.00	678.49	485.21	349.62	244.31
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	2377.45	1771.10	1773.82	1276.46	1085.44	918.30
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	601.28	2304.23	2182.53	1569.98	1106.89	740.64
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	229.27	219.36	343.09	833.25	506.39	298.89
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	1275.13	1396.83	1341.96	1073.18	891.41	669.93
Sundry Debtors	1201.20	988.33	421.86	784.11	539.78	621.66
Cash and Bank	28.46	21.90	61.44	37.13	150.80	15.63
Loans and Advances	275.44	337.41	482.37	256.95	254.04	368.47
Total Current Assets	2780.23	2744.47	2307.63	2151.37	1836.03	1675.69
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	830.04	871.72	772.70	615.29	648.40	742.25
Provisions	69.96	63.64	53.71	38.17	32.37	34.40
Total Current Liabilities	900.00	935.36	826.41	653.46	680.77	776.65
Net Current Assets	1880.23	1809.11	1481.22	1497.91	1155.26	899.04
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	161.30	151.29	142.80	114.49	95.59	73.86
Deferred Tax Liability	83.14	197.69	188.92	160.25	140.86	118.50
Net Deferred Tax	78.16	-46.40	-46.12	-45.76	-45.27	-44.64
Total Assets	5166.39	6057.40	5734.54	5131.84	3808.71	2812.23
Contingent Liabilities	117.45	62.87	100.46	190.28	259.35	196.18

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	39.31	39.31	39.31	37.70	37.70	37.70
Reserves Total	4331.16	5198.23	5027.66	3181.71	2681.12	2182.44
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	4370.47	5237.54	5066.97	3219.41	2718.82	2220.14
Minority Interest	0.00	0.00	0.00	-28.96	-0.79	0.31
Secured Loans	165.08	0.00	0.02	0.04	34.93	46.53
Unsecured Loans	556.94	717.11	583.59	1747.45	1093.50	661.25
Total Debt	722.02	717.11	583.61	1747.49	1128.43	707.78
Policy Holders Fund	0.00	0.00	0.00	0.00	0.00	0.00
Other Liabilities	106.20	95.82	85.52	147.81	52.03	40.76
Total Liabilities	5198.69	6050.47	5736.10	5085.75	3898.49	2968.99
APPLICATION OF FUNDS :
Gross Block	3706.87	2840.34	2545.41	2132.42	1522.57	1242.44
Less: Accumulated Depreciation	1308.42	1042.49	756.99	580.58	364.12	249.06
Less: Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	2398.45	1797.85	1788.42	1551.84	1158.45	993.38
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	601.28	2304.23	2182.53	1846.18	1551.23	1010.15
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	96.33	118.40	236.28	17.62	48.76	41.64
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	1475.27	1609.70	1486.15	1187.53	967.26	733.93
Sundry Debtors	1046.40	807.13	348.58	864.75	488.92	526.34
Cash and Bank	82.27	69.43	105.84	80.75	205.62	89.92
Loans and Advances	306.08	374.53	524.48	329.72	295.96	474.55
Total Current Assets	2910.02	2860.79	2465.05	2462.75	1957.76	1824.74
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	914.08	1007.92	914.53	852.92	824.56	902.20
Provisions	70.06	63.64	54.14	38.19	36.00	34.40
Total Current Liabilities	984.14	1071.56	968.67	891.11	860.56	936.60
Net Current Assets	1925.88	1789.23	1496.38	1571.64	1097.20	888.14
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	206.15	203.57	184.71	148.06	122.12	83.04
Deferred Tax Liability	83.14	197.69	188.92	160.25	140.86	118.50
Net Deferred Tax	123.01	5.88	-4.21	-12.19	-18.74	-35.46
Other Assets	53.74	34.88	36.70	110.66	61.59	71.14
Total Assets
Contingent Liabilities	109.23	62.87	100.46	117.80	103.98	94.04

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019
Cash and Cash Equivalents at Beginning of the year	13.56	53.66	35.59	144.25	9.45
Net Cash from Operating Activities	730.25	545.26	1388.48	539.75	808.79
Net Cash Used In Investing Activities	-460.98	-368.72	-836.65	-821.91	-753.66
Net Cash Used In Financing Activities	-261.16	-216.64	-533.76	166.13	79.67
Net Inc./Dec In Cash And Cash Equivalents	8.11	-40.10	18.07	-116.03	134.80
Cash And Cash Equivalents At End Of The Year	21.67	13.56	53.66	28.22	144.25

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

69.61%

FII Shareholding

4.46%

DII Shareholding

15.38%

Public Shareholding

10.54%

**Promoter pledged shareholding 69.61%

About Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 19472.53 crores. It has reported a sales of Rs. 1588.39 crores and a net profit of Rs. 233.24 crores for the quarter ended December 2018. The company management includes Chirayu R Amin, Chirayu R Amin,Pranav N Parikh,K G Ramanathan,Paresh Saraiya,Rajkumar Baheti,Pranav Amin,Shaunak Amin,Archana Hingorani,Ashok Barat,Manisha Saraf,Jai S Diwanji (Alembic Pharmaceuticals Ltd) among others.

Chairman

Chirayu R Amin

Registered office

Alembic Road,,Vadodara,Gujarat,390003

FAX :91-0265-2282506

Background

Incorporation Year2010

Face Value₹2

Market Lot1

How to buy Alembic Pharma shares on nse?

To buy Alembic Pharma shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Alembic Pharma share price today?

The Alembic Pharma shares price on nse is Rs.990.25 today.

What is the market cap of Alembic Pharma shares on NSE ?

The company has a market capitalization of Rs.19464.66Cr

What is the PE & PB ratio of Alembic Pharma shares ?

PE is 32.72 and PB is 4.34

What is the 52 Week High and Low of Alembic Pharma shares?

Alembic Pharma stock price high: Rs.1094 Alembic Pharma stock price low: Rs.542.4

How can I purchase stock in Alembic Pharma?

You can use the services of a reliable broker like Motilal Oswal to purchase stock in Alembic Pharma. All you have to do is sign up with the broker and open demat and trading accounts. You can buy stocks in Alembic Pharma on the stock exchange through the broker.

Is Alembic Pharma a good investment?

According to some analysts, Alembic Pharma is an undervalued stock at present. Still, it may be a good investment if you are thinking of a long-term view as the stock may see an upside in the future.

Is Alembic Pharma debt-free?

In September 2022, Alembic Pharma held debt at approximately Rs. 7.71 billion, down from the previous year.

What is the dividend yield of Alembic Pharma?

The dividend yield of Alembic Pharma is 2.09% (March 2022).